Skip to main content
Jeffrey Cranmer on Muck Rack

Jeffrey Cranmer

Verified
San Carlos
As seen in: BioCentury, BioCentury This Week
Executive Editor, BioCentury; Host, BioCentury This Week podcast. Jersey boy happily ensconced in Cali. Dad. Iggles fan. Cats. @Princeton, @SAISHopkins alum.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeffrey

Contact Jeffrey, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Portal launches to seed Chicago start-ups

|
By Jeffrey Cranmer Verified
| BioCentury Verified
Having trouble accessing articles? Reset your cache. By Jeff Cranmer, Executive Editor | Mar 6, 2020 | 12:25 AM GMT Portal Innovations launched to seed life sciences, medtech and bioinformatics companies, with a focus on biotechs developing therapeutics, and plans to house the start-ups in Read the full 258 word article User Sign In Sign in to your BioCentury account to access your content. Trial Subscription Get a two-week free trial subscription to BioCentury SIGN UP
Open in Who Shared Issue with article?

New Therapeutic Targets and Biomarkers: January 2019

|
By Jeffrey Cranmer Verified
| BioCentury Verified
1:37 PM Feb 14, 2019 by Jeff Cranmer Share Text Size A A A Print PDF New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January.
Open in Who Shared Issue with article?

Zealand brings in $205M for pipeline via royalty pharma deal

|
By Jeffrey Cranmer Verified
| BioCentury Verified
3:43 PM Sep 13, 2018 Print PDF Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million.Sanofi (Euronext:SAN; NYSE:SNY), Zealand’s partner since 2003, markets Zealand’s lixisenatide... Read the full 205 word article
Open in Who Shared Issue with article?
See all 9 articles